The global Liposomal Doxorubicin Market is projected to witness a higher CAGR during the forecast period. Liposomal anthracyclines lessen the risk of heart disease when compared to the usual doxorubicin while maintaining the anti-tumor capabilities. Liposomal doxorubicin formulations comprise liposomal doxorubicin blended with the peglyated liposomal doxorubicin. Simply put, peglyation is a process comprising doxorubicin wrapped under a PED layer. Peglyation hence protects liposomes from mononuclear phagocyte system.
The drivers for liposomal doxorubicin market include rise in ovarian and breast cancer coupled with increasing awareness for liposomal doxorubicin formulation. Rise in use of drug formulation for ovarian treatment contributes to the market growth during the forecast period. WHO estimates a rise in cancer by 40% by next two decades, which implies the need for better treatment and demand for advanced doxorubicin with liposomal formulation. Rise in geriatric population fuels the market demand coupled with rise in number of approvals for generic formulations.
Full Research Report On Global Liposomal Doxorubicin Market Analysis available at: https://www.millioninsights.com/industry-reports/liposomal-doxorubicin-market
By formulation, the market segmentation includes powder and solution. By cancer type, the market is segmented as prostate cancer, breast cancer, lung cancer, ovary cancer, bladder cancer, stomach cancer and Leukemia. By distribution channel, the liposomal doxorubicin market includes retail pharmacies, hospital pharmacy and e-commerce. Product segment includes J&J, Sun Pharma and Teva. Application category includes ovarian, breast, kidney cancer, multiple myeloma and kaposi sarcoma.
Geographical segmentation for liposomal doxorubicin market include North America, South America, Europe, Asia-Pacific, Europe, Middle East and Africa. North America dominates the market growth during the forecast period owing to high prevalence of breast, liver and ovarian cancers. Asia-Pacific market is highly anticipated to enjoy a steady growth in the forecast period. The key players in the liposomal doxorubicin industry include Johnson & Johson, Mercek & Co, CiplaInc, SRS Pharmaceuticals Inc and Cadila Pharmaceuticals.
Request for Free Sample Copy @ https://www.millioninsights.com/industry-reports/liposomal-doxorubicin-market/request-sample
Liposomal Doxorubicin Product outlook (Market revenue in USD Million, 2013 – 2024)
• J&J (Doxil/Caelyx)
• Sun Pharma (Lipodox)
• Teva (Myocet)
Liposomal Doxorubicin Application Outlook (Market revenue in USD Million, 2013 – 2024)
• Ovarian Cancer
• Multiple Myeloma
• Kaposi Sarcoma
• Bone Sarcoma
• Breast Cancer
• Endometrial Cancer
• Gastric Cancer
• Liver Cancer
• Kidney Cancer
• Other Cancer
Liposomal Doxorubicin Regional Outlook (Market Revenue in USD Million, 2013 – 2024)
• North America
• Asia Pacific
• Latin America
• Middle East and Africa
• South Africa
Related Reports of This Category Available at Million Insights: https://www.millioninsights.com/industry/pharmaceuticals
About Million Insights
Million Insights, is a distributor of market research reports, published by premium publishers only. We have a comprehensive market place that will enable you to compare data points, before you make a purchase. Enabling informed buying is our motto and we strive hard to ensure that our clients get to browse through multiple samples, prior to an investment. Service flexibility & the fastest response time are two pillars, on which our business model is founded. Our market research report store, includes in-depth reports, from across various industry verticals, such as healthcare, technology, chemicals, food & beverages, consumer goods, material science & automotive.
For More Information: www.millioninsights.com
Company Name: Million Insights
Contact Person: Ryan Manuel
Email: Send Email
Address:Office No. 302, 3rd Floor, Manikchand Galleria, Model Colony, Shivaji Nagar